Unlock instant, AI-driven research and patent intelligence for your innovation.

Condensed 5-oxazolidinone derivative

A compound and alkyl technology, applied in the introduction of heterocyclic compound isotopes, drug combination, blood diseases, etc., can solve problems such as serious adverse reactions that hinder hemostasis

Inactive Publication Date: 2016-11-09
SUMITOMO DAINIPPON PHARMA CO LTD
View PDF9 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

)", showing an excellent antithrombotic effect, however, this anticoagulant drug disadvantageously hinders hemostasis and causes serious adverse reactions of hemorrhagic complications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Condensed 5-oxazolidinone derivative
  • Condensed 5-oxazolidinone derivative
  • Condensed 5-oxazolidinone derivative

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0898] The present invention will be described in further detail below in relation to Reference Examples, Examples, and Test Examples, but the present invention is not limited thereto at all. Note that not all the compound names described in the following Reference Examples and Examples are named according to the International Union of Pure and Applied Chemistry (IUPAC). Note that abbreviations may be used herein to simplify the description and have the same meanings as those described above.

[0899] The following abbreviations may be used here.

[0900] The following abbreviations can be used in the NMR data of Reference Examples and Examples.

[0901] Me:methyl

[0902] Et: ethyl

[0903] Bu: Butyl

[0904] tert-: tert

[0905] Boc: tert-butoxycarbonyl

[0906] Tf: Trifluoromethanesulfonyl

[0907] THF: Tetrahydrofuran

[0908] DMF:N,N-Dimethylformamide

[0909] TFA: Trifluoroacetic acid

[0910] DBU:1,8-Diazabicyclo[5.4.0]undec-7-ene

[0911] WSC·HCl: 1-ethyl-3-...

reference example 1

[0952] (1S)-1-[trans-4-({(2S,3S)-3-cyclohexyl-2-[(3,3-dimethyl-1-oxo-1H-[1,3] Azolo[3,4-a]indol-7-yl)carbamoyl]piperidin-1-yl}carbonyl)cyclohexyl]-2-fluoroethyl}carbamate tert-butyl

[0953]

[0954] At room temperature, stir the compound of reference example 1-8 (77.4mg, 0.179mmol), the compound of reference example 1-3 (57.0mg, 0.200mmol), 1-hydroxybenzotriazole (41.1mg, 0.269mmol), WSC. A mixture of HCl (51.5 mg, 0.269 mmol), triethylamine (62.3 μl, 0.448 mmol), and DMF (3 mL) was carried out for 3 hours. To the reaction mixture was added saturated aqueous ammonium chloride, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed twice with saturated aqueous ammonium chloride solution and once with saturated aqueous sodium bicarbonate solution and saturated brine solution, then dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography to...

reference example 1-2

[0962] Methyl trans-4-(fluoroacetyl)cyclohexanecarboxylate

[0963]

[0964] To a solution of the compound of Reference Example 1-1 (7.00 g, 24.62 mmol) in acetonitrile (50 mL) was added Selectfluor (13.08 g, 36.92 mmol) at room temperature and the resulting mixture was stirred at 40° C. for 4 hours and then at room temperature 13 hours. To the reaction solution was added saturated aqueous sodium thiosulfate solution, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate solution, saturated aqueous ammonium chloride solution, and saturated brine solution, then dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product (6.78 g).

[0965] To a solution of the obtained crude product (6.64 g, 21.96 mmol) in chloroform (30 mL) was added trifluoroacetic acid (15.02 g, 131.7 mmol) at room temperature, and the resulting mixture was stirred at 40°C for ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
lengthaaaaaaaaaa
Login to View More

Abstract

Provided are condensed 5-oxazolidinone derivatives and pharmaceutically permissible salts thereof, which have excellent anticoagulant effects, are well absorbed orally, and are useful as therapeutic drugs for thrombosis, etc. Compounds represented by formula (1) and pharmaceutically permissible salts thereof. In the formula, L represents a C1-C4 alkylene group that may be substituted; R11 and R12 each independently represent a hydrogen atom or C1-C6 alkyl group, etc. that may be substituted; X1 represents N or CR1; R1 and R2 each independently represent a hydrogen atom, halogen atom, or C1-C6 alkyl group; Ra represents a C4-C7 cycloalkyl group, etc. that may be substituted; and Rb represents a hydrogen atom, etc.

Description

technical field [0001] The present invention relates to new condensation 5- The oxazolidinone derivative or a pharmaceutically acceptable salt thereof can be orally administered as an anticoagulant drug. Background technique [0002] Atherosclerotic thrombosis, which induces myocardial infarction, cerebral infarction, etc., and develops due to arteriosclerosis, and deep venous thrombosis, which induces pulmonary embolism, are the main causes of human death. Warfarin, which is currently the most commonly used anticoagulant drug, is indicated for "treatment and prevention of thromboembolism (venous thrombosis, myocardial infarction, pulmonary embolism, cerebral embolism, slowly progressive cerebral thrombosis, etc.)", showing However, this anticoagulant drug disadvantageously hinders hemostasis and causes serious adverse reactions of bleeding complications. In this context, there is a strong demand for the development of therapeutic and preventive agents with new mechanisms...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D498/04A61K31/404A61K31/424A61K31/454A61P7/02A61P43/00C07D403/12C07D498/10C07D498/20
CPCA61K31/424A61K31/454A61K45/06A61P7/02A61P43/00C07D401/14C07D403/12C07D498/04A61K2300/00A61K31/404C07D498/10C07D498/20C07B59/002C07B2200/05C12P17/165C12P17/188
Inventor 井熊洋平岩田昌门李钟光
Owner SUMITOMO DAINIPPON PHARMA CO LTD